passiv
immun
passiv
immun
passiv
immunotherapi
refer
transfer
antibodi
unprotect
individu
prevent
treatment
diseas
first
formal
demonstr
passiv
immun
success
treat
diphtheria
tetanu
date
back
anim
studi
publish
deutsch
medizinisch
wochenschrift
german
medic
journal
techniqu
quickli
adapt
clinic
use
earli
diphtheriaspecif
antitoxin
use
success
hospit
set
reduc
mortal
diphtheria
outbreak
inde
emil
von
behr
award
first
nobel
prize
physiolog
medicin
discoveri
import
medic
intervent
signific
clinic
advanc
overst
behr
estim
live
save
year
use
diphtheriaspecif
passiv
immunotherapi
germani
alon
mortal
rate
hospit
case
rang
work
emil
von
behr
colleagu
shibasaburo
kitasato
provid
hope
diphtheria
patient
preantibiot
era
accord
behr
discoveri
passiv
immun
would
occur
earlier
work
focus
character
protect
mechan
activ
immun
diphtheria
work
collabor
kitasato
mechan
vaccinemedi
immun
tetanu
guinea
pig
infect
corynebacterium
diphtheria
anim
routin
die
diseas
howev
behr
vaccin
anim
mount
neutral
antibodi
diphtheria
toxin
found
protect
normal
lethal
dose
c
diphtheria
determin
protect
intrins
properti
immun
host
could
transfer
suscept
host
inject
guinea
pig
diphtheria
toxin
success
treat
immun
serum
vaccin
anim
likewis
inject
clostridium
tetani
purifi
tetanu
toxin
typic
lethal
method
develop
paul
ehrlich
anim
could
eventu
becom
immun
high
dose
tetanu
toxin
sequenti
inocul
lower
nonleth
dose
tetanu
toxin
kitasato
use
approach
demonstr
blood
vaccin
tetanusimmun
rabbit
could
transfer
mice
fulli
protect
normal
lethal
dose
virul
c
tetani
filter
c
tetani
cultur
supernat
contain
tetanu
toxin
behr
kitasato
may
said
best
final
sentenc
landmark
studi
result
experi
remind
us
forcibl
word
blut
ist
ein
ganz
besonder
saft
blood
unusu
fluid
technolog
advanc
substanti
year
sinc
behr
kitasato
first
formal
demonstr
protect
passiv
immunotherapi
earli
day
infeas
use
human
immun
serum
treat
diphtheria
first
largescal
product
polyclon
diphtheriaimmun
serum
prepar
vaccin
dairi
cow
day
commerci
antisera
use
treat
broad
rang
toxin
still
produc
anim
tabl
passiv
immunotherapi
animalderiv
antibodi
prepar
use
close
medic
supervis
result
host
immun
respons
foreign
immunoglobulin
serum
protein
may
trigger
serum
sick
urticaria
andor
anaphylaxi
follow
administr
fortun
advent
sever
innov
technolog
reduc
need
animalderiv
antibodi
forg
new
path
term
safeti
feasibl
protect
efficaci
afford
passiv
immun
follow
discoveri
monoclon
antibodi
technolog
refin
made
includ
use
variou
display
techniqu
eg
phage
display
yeast
display
screen
larg
antibodi
librari
technolog
advanc
includ
develop
chimer
monoclon
antibodi
murin
antibodi
human
genet
replac
heavi
chain
region
molecul
human
immunoglobulin
counterpart
use
transgen
mice
endogen
murin
immunoglobulin
gene
replac
human
immunoglobulin
gene
latter
approach
advantag
hybridoma
immun
transgen
mice
produc
fulli
human
monoclon
antibodi
without
requir
genet
modif
recent
develop
epsteinbarr
viru
ebv
transform
human
memori
b
cell
product
monoclon
antibodi
led
yet
anoth
surg
product
new
human
monoclon
antibodi
rare
antigen
specif
uncommon
pathogen
produc
directli
immun
human
subject
era
antibiot
antibodybas
therapi
option
avail
combat
mani
bacteri
diseas
even
today
hand
antivir
drug
avail
therapeut
option
exist
viral
diseas
howev
new
antibodybas
therapi
continu
develop
potenti
provid
protect
broad
array
bacteri
viral
pathogen
chapter
describ
role
passiv
immun
protect
host
discuss
paramet
involv
success
immunotherapi
provid
exampl
protect
efficaci
anim
model
well
human
clinic
studi
age
born
mother
receiv
pertussi
vaccin
pregnanc
thu
lend
support
current
recommend
vaccin
pregnant
mother
b
pertussi
age
limit
younger
month
chosen
age
primari
pediatr
vaccin
recommend
analysi
beyond
age
might
confound
protect
effect
direct
vaccin
child
nevertheless
protect
afford
matern
deriv
igg
respiratori
infect
involv
viral
eg
influenza
bacteri
eg
b
pertussi
pathogen
togeth
demonstr
broad
impact
matern
vaccin
subsequ
increas
transfer
matern
antibodi
health
young
infant
vaccin
antibiot
revolution
modern
medicin
antibodybas
therapi
repres
effect
medic
treatment
mani
lifethreaten
diseas
includ
diphtheria
scarlet
fever
bacteri
mening
bacteri
pneumonia
today
commerci
form
antibodybas
immunotherapi
infecti
diseas
still
reli
polyclon
antibodi
human
anim
origin
notabl
except
monoclon
antibodi
palivizumab
raxibacumab
see
tabl
main
advantag
use
polyclon
antibodi
passiv
immunotherapi
approach
includ
antibodi
multipl
epitop
specif
may
work
addit
synergist
manner
potenti
contribut
multipl
immunoglobulin
isotyp
subclass
differ
biolog
function
tabl
hand
sever
potenti
challeng
use
polyclon
antibodi
immunotherapi
includ
low
antigenspecif
activ
suppli
limit
especi
rare
diseas
variabl
manufactur
lot
safeti
well
qualiti
control
issu
often
associ
use
human
blood
product
ungul
differ
also
indic
care
taken
choos
appropri
anim
model
studi
role
matern
antibodi
infecti
diseas
mechan
may
speciesspecif
typic
realiz
comprehens
studi
involv
analysi
antibodi
virus
use
sampl
patient
relationship
matern
immun
infant
immun
clear
fig
preval
antibodi
viral
antigen
among
infant
less
month
old
remark
similar
observ
old
adult
repres
main
age
group
mother
instanc
immun
common
childhood
diseas
measl
mump
compar
newborn
mother
immun
lesscommon
viral
pathogen
influenza
b
rel
low
among
infant
adult
cohort
examin
higher
among
sampl
coincid
influenza
b
epidem
occur
show
preval
matern
antibodi
dynam
recent
outbreak
involv
specif
pathogen
result
higher
frequenc
pathogenimmun
mother
concomit
increas
number
infant
likewis
bestow
least
transient
immun
particular
microb
expect
matern
antibodi
wane
rapidli
first
month
life
exposur
pathogen
follow
month
year
result
accumul
differ
antibodi
specif
children
reach
adulthood
see
fig
overal
protect
efficaci
matern
antibodi
perhap
pronounc
among
children
genet
immunodefici
sever
combin
immunodefici
scid
result
lack
function
b
cell
agammaglobulinemia
patient
lack
function
b
cell
still
abil
mount
pathogenspecif
tcell
respons
clinic
present
scid
appar
birth
rel
uniform
diagnosi
occur
mean
month
age
also
age
matern
antibodi
reach
lowest
level
see
fig
likewis
agammaglobulinem
patient
also
begin
present
symptom
immunodefici
around
age
matern
antibodi
repres
immunolog
doubleedg
sword
sens
known
interfer
live
attenu
viru
vaccin
mmr
measl
mump
rubella
rotaviru
vaccin
wherea
direct
immun
mother
third
trimest
pregnanc
significantli
increas
protect
infant
common
respiratori
virus
influenza
inde
matern
vaccin
may
result
reduct
influenzarel
hospit
among
infant
younger
month
age
likewis
import
matern
vaccin
bordetella
pertussi
ie
whoop
cough
recogn
earli
studi
show
higher
antibacteri
antibodi
respons
potenti
protect
exposur
whoop
cough
among
infant
born
vaccin
mother
recent
studi
verifi
earlier
result
demonstr
vaccin
efficaci
whoop
cough
among
infant
younger
month
nonlymphoid
tissu
penetr
mucos
site
infect
like
explain
often
consid
best
immunoglobulin
isotyp
routin
passiv
immun
shown
clinic
benefit
rang
reduc
clinic
symptom
nearli
complet
protect
lethal
infect
number
infecti
diseas
model
tabl
last
centuri
well
establish
high
specif
antibodi
titer
earli
time
antibodi
transfer
relat
diseas
onset
two
import
paramet
involv
determin
protect
efficaci
passiv
immun
fig
one
account
earli
day
clinic
diphtheriaspecif
immunotherapi
develop
behr
ehrlich
initi
failur
patient
treatment
weak
unstandard
diphtheriaimmun
serum
brought
ehrlich
describ
three
point
believ
import
success
immunotherapi
treatment
initi
onset
diseas
b
diseas
progress
higher
serum
quantiti
necessari
cure
c
depend
sever
case
certain
minim
dose
specifi
later
studi
confirm
result
diphtheria
immunotherapi
initi
first
day
diseas
mortal
n
howev
therapi
delay
day
diseas
onset
accompani
diphtheria
casefat
rate
subsequ
increas
n
n
n
respect
result
similar
observ
antibioticbas
therapi
bacteri
sepsi
ideal
set
recommend
antibiot
administ
within
hour
diagnosi
sever
sepsi
septic
shock
drug
provid
clinic
benefit
administ
earli
cours
diseas
gener
ineffect
latestag
diseas
import
highdos
immunotherapi
given
earliest
sign
diseas
uniqu
bacteri
antitoxin
therapi
rule
appli
prevent
treat
viral
infect
well
measl
epidem
expos
individu
n
receiv
passiv
immun
contract
measl
convalesc
serum
administ
within
day
exposur
attack
rate
reduc
n
wherea
therapi
initi
day
postexposur
approxim
contrast
monoclon
antibodi
definit
limit
singl
epitop
specif
sever
advantag
polyclon
antibodi
sinc
manufactur
vitro
larg
scale
inher
high
specif
lot
consist
tabl
exampl
combin
mg
two
tetanusspecif
human
monoclon
antibodi
neutral
capac
observ
administr
mg
polyclon
tetanu
immunoglobulin
likewis
administr
mg
vaccinia
virusspecif
monoclon
antibodi
provid
level
protect
afford
mg
vaccinia
immunoglobulin
vig
although
neutral
escap
mutant
valid
concern
use
monoclon
antibodi
therapi
yet
major
problem
clinic
use
palivizumab
respiratori
syncyti
viru
rsv
initi
sequenc
rsv
isol
demonstr
mutat
neutral
epitop
f
protein
subsequ
studi
identifi
rsv
escap
mutant
approxim
breakthrough
case
indic
select
pressur
escap
mutat
still
rel
uncommon
current
condit
use
suggest
monoclon
antibodi
remain
effect
use
clinic
longterm
long
specif
stabl
epitop
particular
pathogen
function
characterist
immunoglobulin
use
passiv
immun
import
consider
determin
protect
efficaci
vivo
exampl
serum
igg
molecul
equilibr
extravascular
space
wherea
igm
larg
confin
intravascular
space
igm
molecul
also
short
halflif
day
typic
low
affin
igm
optim
choic
passiv
immunotherapi
serum
iga
monomer
although
also
equilibr
extravascular
space
halflif
appear
contribut
significantli
function
iga
lung
mice
human
igg
hand
averag
halflif
approxim
day
except
igg
halflif
typic
high
affin
transud
across
mucos
barrier
protect
pathogen
invad
mucos
rout
interestingli
serum
igg
serum
iga
respons
elicit
respons
vaccin
neisseria
meningitidi
correl
strongli
level
antibacteri
antibodi
present
saliva
month
year
vaccin
indic
circul
serum
antibodi
may
import
contributor
antibodi
releas
mucos
secret
inde
intraven
administr
hivspecif
monoclon
antibodi
rhesu
macaqu
serum
antibodi
titer
result
mucos
antibodi
titer
vagin
fluid
provid
complet
protect
intravagin
challeng
shiv
chimer
simian
immunodefici
viru
express
hiv
envelop
influenza
viru
anoth
mucos
pathogen
strict
tropism
respiratori
tract
influenzaspecif
serum
antibodi
titer
correl
protect
human
mice
rel
role
influenzaspecif
polymer
iga
igg
compar
term
antivir
protect
upper
respiratori
tract
versu
lung
influenza
challeng
polymer
iga
transfer
hour
prior
influenza
infect
prevent
patholog
upper
respiratori
tract
effect
lung
wherea
transfer
igg
prevent
patholog
lung
requir
higher
dose
protect
infect
upper
respiratori
tract
author
conclud
differ
antibodi
isotyp
may
function
preferenti
differ
anatom
site
vivo
result
contrast
experiment
influenza
infect
human
inactiv
influenza
vaccinederiv
igg
believ
major
contributor
protect
nasal
compart
overal
abil
igg
enter
efficaci
passiv
immun
decreas
diseas
progress
full
protect
symptomat
diseas
best
achiev
prophylact
administr
antibodi
therapi
prior
exposur
infect
howev
antibodi
therapi
may
also
highli
effect
earli
point
postexposur
prior
onset
diseas
symptom
passiv
immun
gener
less
effect
administ
onset
symptomat
diseas
typic
show
littl
clinic
benefit
sever
latestag
diseas
occur
iuml
postexposur
incid
measl
increas
despit
either
lot
administ
within
day
exposur
likewis
time
passiv
immunotherapi
also
import
enter
eg
polio
respiratori
pathogen
eg
rsv
outbreak
involv
polio
patient
show
convalesc
serum
administ
within
day
mening
paralysi
report
patient
n
treatment
delay
day
mening
diseas
onset
report
paralysi
n
treatment
delay
day
paralysi
note
polio
patient
n
rsv
polyclon
rsvimmunoglobulin
reduc
incid
rsvassoci
hospit
contact
subsequ
contract
measl
n
studi
publish
involv
case
measl
exposur
individu
receiv
immunotherapi
within
day
exposur
contract
measl
compar
whose
treatment
delay
day
postexposur
dose
use
studi
also
critic
patient
receiv
mlkg
gammaglobulin
contract
measl
wherea
patient
receiv
mlkg
gammaglobulin
contract
diseas
titer
virusspecif
antibodi
often
differ
lot
polyclon
immunoglobulin
prepar
see
tabl
anoth
studi
measlesspecif
titer
gammaglobulin
differ
lot
decreas
iuml
anim
studi
prophylaxi
defin
antibodi
administr
prior
experiment
infect
treatment
defin
antibodi
administr
infect
clinic
studi
prophylaxi
defin
antibodi
administr
prior
diseas
onset
treatment
defin
antibodi
administr
diseas
onset
b
evid
provid
matern
immun
studi
c
anecdot
result
defin
small
studi
indic
passiv
immun
may
provid
clinic
benefit
limit
scope
conclus
avail
although
two
studi
demonstr
prophylaxi
direct
mix
mump
viru
antibodi
prior
inocul
confirm
lassa
fever
receiv
immun
serum
within
day
hospit
surviv
howev
treatment
initi
day
hospit
patient
surviv
similar
untreat
group
patient
virolog
confirm
lassa
fever
surviv
although
passiv
immun
toxin
system
infect
measl
smallpox
well
establish
impact
approach
prevent
amelior
diseas
caus
respiratori
enter
pathogen
may
well
recogn
howev
sever
studi
support
role
passiv
immun
mucos
pathogen
see
tabl
includ
exampl
influenza
respiratori
viru
haemophilu
influenza
respiratori
bacterium
rotaviru
enter
viru
escherichia
coli
enter
bacterium
influenza
signific
caus
morbid
mortal
throughout
world
includ
season
transmiss
pandem
outbreak
clinic
correl
homotyp
influenza
immun
vaccineassoci
protect
recogn
earli
develop
influenza
vaccin
earli
anim
studi
confirm
result
passiv
transfer
antibodi
system
mucos
deliveri
abl
protect
anim
subsequ
challeng
provid
therapeut
benefit
administ
postexposur
recent
anim
studi
defin
monoclon
antibodi
continu
support
extend
earlier
result
passiv
immun
influenza
human
also
success
comprehens
retrospect
metaanalysi
eight
passiv
immun
studi
perform
spanish
influenza
outbreak
signific
decreas
mortal
confid
interv
ci
p
observ
subset
analysi
studi
record
earli
treatment
initi
within
day
pneumonia
complic
versu
late
intervent
day
show
signific
advantag
earli
treatment
mortal
decreas
earlier
intervent
consist
gener
consider
effect
passiv
immun
infecti
diseas
see
fig
recent
doubleblind
random
control
studi
influenza
pandem
use
hyperimmun
intraven
immunoglobulin
ivig
recov
convalesc
donor
compar
normal
ivig
treatment
sever
infect
subject
hyperimmun
treat
group
n
demonstr
rapid
viral
clearanc
control
group
n
greater
drop
viral
load
day
posttreat
patient
receiv
immunoglobulin
within
day
symptom
onset
n
receiv
hyperimmun
ivig
surviv
wherea
patient
receiv
normal
ivig
surviv
p
h
influenza
type
b
hib
extracellular
gramneg
bacterium
initi
infect
host
via
respiratori
tract
repres
anoth
import
human
pathogen
control
passiv
immun
sever
earli
report
describ
use
concentr
rabbit
immun
serum
success
adjunct
therapi
sulfonamid
treatment
patient
suffer
hib
mening
inde
full
cours
serum
therapi
addit
antibiot
abl
reduc
mortal
compar
mortal
rate
patient
receiv
sulfonamid
recent
studi
establish
prophylact
among
children
histori
prematur
bronchopulmonari
dysplasia
prophylact
administr
neutral
monoclon
antibodi
palivizumab
shown
significantli
improv
clinic
outcom
reduc
rsvassoci
hospit
children
congenit
heart
diseas
among
prematur
infant
bronchopulmonari
dysplasia
rsvassoci
hospit
reduc
third
palivizumab
studi
confirm
result
show
reduct
hospit
among
prematur
infant
infant
chronic
lung
diseas
anoth
monoclon
antibodi
motavizumab
demonstr
rel
reduct
rsv
hospit
compar
patient
receiv
palivizumabbas
prophylaxi
contrast
rsv
infect
establish
use
palivizumab
motavizumab
rsvimmunoglobulin
show
clinic
benefit
although
rsvimmunoglobulin
may
provid
limit
protect
sever
case
passiv
immunotherapi
highli
success
sever
even
lifethreaten
human
diseas
smallpox
hemorrhag
fever
caus
arenavirus
includ
junin
lassa
fever
viru
see
tabl
success
intervent
howev
typic
requir
initi
treatment
shortli
symptom
onset
convalesc
serum
smallpox
survivor
administ
smallpox
patient
late
stage
confluent
hemorrhag
smallpox
clinic
benefit
observ
comparison
untreat
control
vs
mortal
respect
vacciniaimmun
gammaglobulin
vig
administ
smallpox
contact
prior
diseas
onset
addit
postexposur
vaccin
ie
standard
care
number
smallpox
case
reduc
compar
contact
receiv
postexposur
smallpox
vaccin
alon
likewis
administr
vacciniaimmun
serum
anim
origin
along
postexposur
vaccin
result
case
smallpox
among
close
contact
compar
case
among
control
receiv
smallpox
vaccin
alon
smallpox
outbreak
patient
die
undergo
standard
clinic
care
determin
addit
passiv
immunotherapi
would
reduc
mortal
smallpox
diagnosi
case
smallpox
treat
convalesc
serum
blood
smallpoxassoci
death
report
approxim
patient
describ
sever
hemorrhag
smallpox
time
treatment
yet
surviv
appear
result
use
convalesc
serum
obtain
peak
humor
immun
respons
shortli
recoveri
smallpox
use
optim
dose
schedul
higher
dose
administ
patient
sever
diseas
manifest
argentin
hemorrhag
fever
caus
infect
junin
viru
untreat
case
result
mortal
convalesc
serum
protect
anim
model
junin
infect
administ
within
day
symptom
onset
mortal
rate
among
human
case
drop
likewis
hospit
case
lassa
fever
viru
caus
sever
diseas
includ
diffus
capillari
leakag
hemorrhag
diathesi
prophylact
administr
immun
serum
protect
guinea
pig
nonhuman
primat
subsequ
lethal
challeng
indic
antibodi
play
clear
role
protect
virul
viral
pathogen
one
small
clinic
studi
passiv
immunotherapi
administ
within
day
admiss
hospit
patient
surviv
wherea
immunotherapi
initi
day
hospit
patient
surviv
anoth
studi
patient
virolog
new
scientif
advanc
controversi
behr
demonstr
immun
serum
therapi
could
protect
diphtheria
went
current
dogma
time
cellular
theori
phagocytosi
believ
primari
mechan
host
protect
also
skeptic
earli
discuss
antibodi
immunotherapi
would
work
howev
scienc
prevail
today
number
passiv
immunotherapi
product
clinic
use
see
tabl
everincreas
number
human
diseas
benefit
use
technolog
see
tabl
believ
antibodi
play
import
role
protect
cytopath
virus
extracellular
bacteria
cell
must
requir
protect
infect
noncytopath
virus
intracellular
pathogen
although
partial
refut
protect
efficaci
matern
antibodi
ivig
therapi
scid
patient
function
cell
import
bear
mind
antibodymedi
protect
passiv
immunotherapi
immunocompet
individu
function
isol
instead
work
best
conjunct
immun
defens
includ
host
cell
b
cell
natur
killer
nk
cell
etc
although
role
antibodymedi
protect
intracellular
bacteria
chronic
viral
infect
thought
rel
minor
exampl
instanc
passiv
immun
provid
substanti
clinic
benefit
note
previous
prior
advent
antibiot
passiv
immunotherapi
option
clinic
treatment
bacteri
infect
includ
francisella
tularensi
facult
intracellular
bacterium
caus
tularemia
sever
diseas
associ
mortal
untreat
case
streptomycin
becam
avail
compar
studi
perform
tularemia
patient
receiv
symptomat
treatment
receiv
immun
equin
serum
receiv
hyperimmun
equin
serum
receiv
streptomycin
untreat
tularemia
case
requir
averag
month
recov
three
mode
therapi
show
substanti
improvementtreat
immun
serum
within
day
diseas
onset
month
recoveri
treatment
hyperimmun
serum
month
recoveri
treatment
streptomycin
month
recoveri
two
clinic
case
extens
describ
follow
summari
clinic
respons
agent
ie
immun
serum
streptomycin
similar
prompt
amelior
symptom
intoxicationheadach
mental
dull
lethargi
sens
prostrat
sever
malais
reduct
fever
size
bubo
acceler
heal
ulcer
resolut
pulmonari
exud
word
passiv
immunotherapi
appear
mani
way
mimic
antibiot
therapi
term
protect
efficaci
howev
note
treatment
equin
serum
caus
serum
sick
patient
variabl
outcom
antibiot
approach
lead
recommend
streptomycin
would
agent
choic
futur
treatment
diseas
recent
develop
polyclon
monoclon
antibodi
show
protect
efficaci
tularemia
anim
model
may
possibl
incorpor
passiv
immunotherapi
antibiot
treatment
clinic
practic
tularemia
bacteri
diseas
especi
case
antibiot
resist
becom
widespread
mycobacterium
tuberculosi
anoth
intracellular
bacterium
despit
avail
antibiot
remain
one
use
human
immunoglobulin
atrisk
popul
santosham
colleagu
administ
hyperimmunoglobulin
n
salin
placebo
n
infant
month
age
examin
rate
invas
hib
first
day
follow
passiv
immun
protocol
none
treat
infant
experienc
invas
hib
incid
compar
placebotr
children
incid
p
rotaviru
repres
enter
viral
pathogen
wherein
protect
passiv
immunotherapi
demonstr
one
exampl
postexposur
treatment
infant
oral
administr
hyperimmun
antibodi
addit
standard
support
care
abl
effici
reduc
rotaviru
shed
compar
placebo
control
treat
patient
n
exhibit
evid
viral
shed
day
posttreat
compar
control
n
separ
studi
prophylact
passiv
immun
use
oral
administ
bovin
colostrum
immun
anim
test
blind
random
trial
among
infant
children
month
old
admit
hospit
typic
respiratori
condit
follow
admiss
infant
given
cours
bovin
colostrum
placebo
infant
receiv
placebo
contract
symptomat
rotaviru
rate
wherea
symptomat
rotaviru
diseas
observ
colostrumtr
infant
p
analysi
rotaviru
vaccin
failur
also
indic
matern
deriv
antibodi
play
role
passiv
immun
rotaviru
infect
studi
involv
vaccin
infant
strong
invers
correl
observ
matern
deriv
rotaviru
antibodi
abil
infant
seroconvert
follow
vaccin
live
rotaviru
vaccin
import
demonstr
passiv
immun
enter
pathogen
also
broader
implic
time
vaccin
administr
especi
develop
countri
preexist
immun
rel
high
rotaviru
vaccin
immunogen
appear
impair
e
coli
signific
enter
pathogen
wherein
prophylaxi
passiv
immun
demonstr
sever
clinic
studi
tacket
colleagu
abl
passiv
protect
human
subject
experiment
induc
e
coli
diarrhea
specif
bovin
antibodi
use
heatinactiv
glutaraldehydeinactiv
e
coli
vaccin
pregnant
cow
hyperimmun
larg
number
enterotoxigen
serogroup
milk
collect
first
day
lactat
purifi
concentr
lyophil
formul
oral
administr
control
similar
prepar
made
use
rotaviru
immun
antigen
subject
receiv
daili
treatment
time
daili
day
e
coli
challeng
administ
day
treatment
regimen
subject
receiv
e
coli
antibodi
prophylaxi
remain
diseasefre
follow
challeng
compar
clinic
diarrhea
placebo
subject
p
use
close
relat
clinic
protocol
otto
colleagu
also
demonstr
good
efficaci
hyperimmun
bovin
colostrum
tablet
first
studi
conduct
trial
placebo
subject
contract
diarrhea
follow
challeng
reduc
treat
subject
p
second
studi
investig
impact
omit
buffer
oral
prophylaxi
author
also
examin
dose
spare
studi
standard
dose
still
confer
signific
protect
treat
subject
contract
diarrhea
compar
control
interestingli
dose
reduc
onehalf
diseas
incid
increas
subject
indic
key
role
play
treatment
dose
achiev
success
passiv
immunotherapi
develop
similar
rate
among
three
group
p
howev
administr
immunoglobulin
typic
perform
first
month
transplant
antivir
antibodi
halflif
estim
approxim
day
surpris
protect
effect
passiv
immunotherapi
maintain
first
year
nevertheless
inadvert
discoveri
protect
role
antibodi
prevent
ebvinduc
nonhodgkin
lymphoma
repres
potenti
breakthrough
clinic
manag
vulner
patient
popul
despit
decad
research
aim
find
vaccin
cure
hiv
infect
viru
remain
scourg
global
proport
earli
attempt
passiv
immunotherapi
use
firstgener
hivspecif
monoclon
antibodi
highli
effect
approach
pursu
new
gener
highli
potent
broadli
neutral
antibodi
identifi
particular
recent
phase
clinic
trial
involv
singl
administr
broadli
neutral
antibodi
renew
interest
studi
passiv
immunotherapi
hiv
prevent
therapeut
intervent
bind
site
antibodi
neutral
hiv
strain
compris
six
differ
clade
test
doseescal
studi
among
hivposit
patient
differ
level
viremia
dose
mgkg
patient
viral
load
reduc
log
averag
declin
log
individu
subject
respond
antibodi
treatment
mgkg
infect
resist
strain
hiv
although
effect
antibodi
therapi
viremia
mainli
transient
singl
administr
viral
load
remain
lower
preexist
set
point
patient
day
one
subject
exhibit
viremia
level
remain
near
limit
detect
throughout
studi
current
unclear
hiv
viremia
patient
eventu
rebound
origin
level
similar
result
observ
antibodybas
therapi
shivinfect
rhesu
macaqu
anim
show
rebound
viral
replic
transfer
monoclon
antibodi
declin
undetect
level
subset
anim
maintain
virolog
control
absenc
infus
combin
antiretrovir
drug
current
standard
care
treatment
hiv
infect
unlik
one
dose
singl
monoclon
antibodi
suffici
longterm
clinic
benefit
among
broad
patient
base
howev
grow
optim
combin
cocktail
potent
broadli
neutral
monoclon
antibodi
antiretrovir
drug
agent
activ
latent
viru
reservoir
could
theoret
provid
longterm
reduct
viral
load
reduc
rate
transmiss
substanti
advanc
monoclon
antibodi
technolog
increas
appreci
role
antibodi
control
infecti
diseas
develop
sophist
new
passiv
immunotherapi
like
continu
acceler
pace
antibiot
resist
among
clinic
relev
bacteria
includ
multidrugresist
mdr
xdr
tuberculosi
methicillinresist
staphylococcu
aureu
mrsa
domin
strain
antibioticresist
salmonella
typhi
gramneg
bacteri
speci
grow
concern
coupl
knowledg
fewer
new
antibiot
move
drug
pipelin
may
motiv
research
develop
antibodybas
therapi
overcom
challeng
clinic
intervent
microbi
diseas
one
drawback
passiv
immun
antibodi
halflif
vivo
common
human
diseas
estim
infect
onethird
world
popul
develop
strain
extens
drugresist
xdr
tuberculosi
tb
resist
current
antibiot
therapi
also
grow
concern
especi
antibiot
drug
pipelin
consider
debat
role
antibodi
control
tb
mani
believ
antibodi
play
littl
role
protect
immun
review
refer
comprehens
histor
review
glatmanfreedman
casadeval
clinic
benefit
antibodymedi
immunotherapi
albeit
quit
variabl
provid
evid
suggest
antibodi
play
role
protect
tb
studi
report
paquin
group
patient
pulmonari
tb
confirm
presenc
bacterium
sputum
show
clinic
benefit
month
passiv
immunotherapi
patient
show
reduc
cough
reduct
bacteri
load
sputum
clearanc
pulmonari
infiltr
reduct
hemoptysi
improv
appetit
weight
gain
month
initi
treatment
treat
patient
aliv
half
discharg
hospit
contrast
untreat
tb
patient
anoth
ward
hospit
die
within
month
start
studi
experiment
proof
antibodymedi
protect
tb
also
publish
fisch
lethal
tb
challeng
guinea
pig
administr
immun
serum
perform
day
dose
administ
everi
day
week
week
fisch
report
treat
anim
aliv
month
surviv
treatment
delay
day
postchalleng
anim
surviv
show
sign
ill
antibodi
treatment
perform
anim
surviv
past
day
approach
use
treat
patient
pulmonari
tb
patient
treat
earliest
stage
diseas
improv
rapidli
passiv
immunotherapi
tuberculin
neg
end
studi
patient
treat
incipi
stage
diseas
longer
bacilli
sputum
consid
cure
show
substanti
improv
diseas
symptom
patient
advanc
tb
show
modest
improv
therapi
conclud
immun
serum
benefici
earli
advanc
case
diseas
ebv
common
human
pathogen
caus
chronic
infect
lead
caus
posttranspl
nonhodgkin
lymphoma
result
uncontrol
prolifer
ebvinfect
b
lymphocyt
patient
undergo
immunosuppress
therapi
larg
retrospect
studi
involv
kidney
transplant
patient
effect
prophylact
treatment
cytomegaloviru
cmv
posttranspl
incid
nonhodgkin
lymphoma
examin
standard
incid
ratio
sir
nonhodgkin
lymphoma
express
number
lymphoma
case
per
person
calcul
normal
age
sex
geograph
origin
patient
receiv
cmv
prophylaxi
sir
remain
unchang
sir
p
among
patient
receiv
antivir
drug
acyclovir
ganciclovir
strike
contrast
patient
receiv
anticmv
immunotherapi
show
complet
absenc
lymphoma
first
year
transplant
sir
p
vs
antivir
treatment
common
anticmv
immunoglobulin
product
shown
contain
antibodi
ebv
believ
mechan
action
protect
afford
first
year
posttransplant
subsequ
year
followup
new
case
lymphoma
suffici
protect
therapeut
intervent
acut
remitt
diseas
activ
immun
improv
vaccin
design
may
still
need
train
host
immun
system
maintain
longterm
level
protect
immun
importantli
exampl
success
passiv
immun
approach
may
provid
use
framework
develop
new
improv
vaccin
elicit
protect
antibodi
respons
refer
chapter
avail
expertconsultcom
often
provid
transient
protect
unless
repeat
administr
perform
may
chang
new
technolog
increas
halflif
monoclon
antibodi
employ
exampl
fc
region
antirsv
monoclon
antibodi
motavizumab
mutat
increas
bind
neonat
fc
receptor
fcrn
result
serum
antibodi
pharmacokinet
human
subject
increas
typic
halflif
halflif
still
retain
virusspecif
neutral
activ
